Contrasting of Odonate Therapeutics Inc. (ODT) and Genprex Inc. (NASDAQ:GNPX)

We will be contrasting the differences between Odonate Therapeutics Inc. (NASDAQ:ODT) and Genprex Inc. (NASDAQ:GNPX) as far as dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Odonate Therapeutics Inc. N/A 0.00 75.94M -3.03 0.00
Genprex Inc. N/A 0.00 9.61M -0.71 0.00

Demonstrates Odonate Therapeutics Inc. and Genprex Inc. earnings per share, top-line revenue and valuation.


Table 2 represents Odonate Therapeutics Inc. (NASDAQ:ODT) and Genprex Inc. (NASDAQ:GNPX)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Odonate Therapeutics Inc. 0.00% -42.8% -40.4%
Genprex Inc. 0.00% -163.8% -144.6%


The current Quick Ratio of Odonate Therapeutics Inc. is 10.9 while its Current Ratio is 10.9. Meanwhile, Genprex Inc. has a Current Ratio of 18.9 while its Quick Ratio is 18.9. Genprex Inc. is better positioned to pay off its short-term and long-term debts than Odonate Therapeutics Inc.

Insider and Institutional Ownership

The shares of both Odonate Therapeutics Inc. and Genprex Inc. are owned by institutional investors at 93.2% and 8.8% respectively. 2.4% are Odonate Therapeutics Inc.’s share owned by insiders. On the other hand, insiders owned about 58.32% of Genprex Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Odonate Therapeutics Inc. -3.93% -15.37% -20.73% -45.14% -34.17% -39.44%
Genprex Inc. -23.03% -24.52% -46.82% -87.9% 0% -75.11%

For the past year Odonate Therapeutics Inc. has stronger performance than Genprex Inc.

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Genprex, Inc., a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome. Genprex, Inc. was founded in 2009 and is based in Austin, Texas.